Boehringer Ingelheim’s Post

Behaviorally's Crispin Beale (Group President) will be speaking TOMORROW at #ContaminAzioni 2024 with Elma Research Italy in Milan! Join us to explore the evolution of market research and gain valuable insights into the pharmaceutical sector! Register here: https://hubs.ly/Q02wcBCZ0 #milan #conference #Elmaresearch #insights #insightsindustry #marketresearch #wearebehaviorally #behaviorallyinc

Read the whitepaper “Beyond Earth’s Gravity” by senior associate Daniel Garcia on a new frontier in pharmaceutical drug research and development, branching beyond traditional ground-based methods and into space. The technological innovations present in the #aerospace and #defense industry provide new #transportation and legal challenges, presenting a unique landscape for pharmaceutical efforts. Dive into the legal implications of space-based drug research and development with our whitepaper. Access the online version here: https://lnkd.in/e9hQ3mum #SpaceandSatellite #Regulatory  

Pharmaceutical manufacturing clients know sustainability goals often clash with reality. In an industry that prioritizes quality and safety, this article explores challenges and opportunities for advancing sustainability and reaching your environmental goals.

Innovation is crucial to succeed in Life Sciences. In response to challenges, PharmaCos are turning to external innovation and broadening their innovation horizon by leveraging licensing deals. Dr. Isabelle Heiber and I have analyzed market developments and how licensing can help life science players to stay competitive. Find more about this topic in our study. #innovation #pharma #licensing #EYParthenon

🔊 Navigating a changing policy landscape for the European life sciences ecosystem: the General Pharmaceutical Legislation 🎤 Vlad Olteanu: “Is important for the pharma strategy to be better correlated with a drug.” 🎤 Georges Siotis: “Multiple challenges mean that you have to maturate and this is part of the direction in which these reform goals.”  🎤 Carlos Buesa: “Unity is a whole system that starts with innovation, financing and access to capital. This is the first step to develop innovative drugs for the future.” 🎤 Caridad Pontes: “Innovation is coming really fast, with an imperative for access across  Europe.”

The Swedish life science sector exemplifies one of the world's most innovative ecosystems. With the pharmaceutical industry accounting for almost 8% of all Swedish investment into R&D, it is evident that Sweden is committed to fostering innovation in this field. Creating a favorable environment for initiating clinical trials is crucial for enhancing the international competitiveness of the Swedish life science sector and attracting investments from global R&D-driven companies. Let's continue the conversation and exchange further insights on this topic! #LifeScience #innovation

nanoencapsulation at reliable quality - prerequisite for easy scale up and for GMP production

Innovation is crucial to succeed in the Life Sciences arena. In response to current challenges, pharmaceutical companies are turning to external innovation, broadening their innovation horizon beyond their in-house R&D. Engaging into licensing deals seems to be an increasingly attractive tool to access innovation. My colleague Rubi Gonzalez and I have analyzed the recent developments in the market. Read our latest study on how licensing can help PharmaCos to access innovation and stay competitive. #innovation #pharma #licensing

Pharmaceutical manufacturing clients know sustainability goals often clash with reality. In an industry that prioritizes quality and safety, this article explores challenges and opportunities for advancing sustainability and reaching your environmental goals.

Europe: a global research and innovation leader? 🌍 Along with our Together4RD project partners, Matt Bolz-Johnson Bolz Johnson and Ines Hernando are among the co-authors of a position statement on the nature of collaboration between the European Reference Networks (ERNs) and the pharmaceutical industry. “ERNs hold major potential to alleviate many of these challenges, and more, but only if adequately supported... To-date, however, ERN-Industry interactions have been largely limited, for a range of reasons (concerning barriers both tangible and perceived).” Read the full article: 📖 https://lnkd.in/eVs3PR9v #Together4Rare #RareDiseases #ERNs #Collaboration #T4RD